Law360, New York (July 27, 2006, 12:00 AM ET) -- When patent owners raise prices and make combination products more expensive in the process, they cannot be sued for monopoly leveraging under U.S. antitrust laws, according to a ruling Wednesday by the U.S. Court of Appeals for the Seventh Circuit.
With the ruling, Judge Frank H. Easterbrook affirmed a lower court’s decision that drug maker Abbott Laboratories Inc. wasn’t violating the Sherman Act when it jacked up the price for its component of a treatment for acquired immune deficiency syndrome.
The class action legal battle surrounds...
Abbott Wins Antitrust Challenge Over HIV Drug Cocktail
To view the full article, take a free trial now.
